Business Description
CVRx Inc
NAICS : 339113
SIC : 3845
ISIN : US1266381052
Total Employee Number:
223Description
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.22 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 2.04 | |||||
Debt-to-EBITDA | -1.29 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -7.19 | |||||
Beneish M-Score | -3.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25.7 | |||||
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | -0.3 | |||||
3-Year FCF Growth Rate | 9.6 | |||||
3-Year Book Growth Rate | -34.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.87 | |||||
9-Day RSI | 46.96 | |||||
14-Day RSI | 46.68 | |||||
3-1 Month Momentum % | -33.42 | |||||
6-1 Month Momentum % | -8.96 | |||||
12-1 Month Momentum % | -29.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.2 | |||||
Quick Ratio | 8.89 | |||||
Cash Ratio | 7.62 | |||||
Days Inventory | 531.15 | |||||
Days Sales Outstanding | 54.55 | |||||
Days Payable | 145.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | -5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.18 | |||||
Operating Margin % | -84.62 | |||||
Net Margin % | -89.15 | |||||
EBITDA Margin % | -77.83 | |||||
FCF Margin % | -67.98 | |||||
OCF Margin % | -66.98 | |||||
ROE % | -108.01 | |||||
ROA % | -46.6 | |||||
ROIC % | -235.89 | |||||
3-Year ROIIC % | -97.49 | |||||
ROC (Joel Greenblatt) % | -279.94 | |||||
ROCE % | -45.59 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.56 | |||||
PB Ratio | 5.25 | |||||
Price-to-Tangible-Book | 5.25 | |||||
EV-to-EBIT | -3 | |||||
EV-to-EBITDA | -3.06 | |||||
EV-to-Forward-EBITDA | -3.93 | |||||
EV-to-Revenue | 2.38 | |||||
EV-to-Forward-Revenue | 1.97 | |||||
EV-to-FCF | -3.5 | |||||
Price-to-GF-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 5.84 | |||||
| Price-to-Net-Cash | 96.33 | |||||
Earnings Yield (Greenblatt) % | -33.33 | |||||
FCF Yield % | -26.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CVRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CVRx Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 59.072 | ||
| EPS (TTM) ($) | -2.02 | ||
| Beta | 1.0462 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 70.06 | ||
| 14-Day RSI | 46.68 | ||
| 14-Day ATR ($) | 0.383083 | ||
| 20-Day SMA ($) | 5.312 | ||
| 12-1 Month Momentum % | -29.86 | ||
| 52-Week Range ($) | 4.3701 - 11.3 | ||
| Shares Outstanding (Mil) | 26.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CVRx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CVRx Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 112 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | In 20 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 19 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:00 | 5.20 (-0.95%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 10:40 | 5.43 (-0.37%) | ||
| General meeting for 2026 | 2026-06-01 10:00 | 5.59 (-0.62%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 16:30 | 6.83 (-5.40%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 6.83 (-5.40%) | ||
| Annual report for 2025 | 2026-02-13 | 5.69 (-6.87%) |
Show
Entries
CVRx Inc Frequently Asked Questions
What is CVRx Inc(CVRX)'s stock price today?
The current price of CVRX is $5.78. The 52 week high of CVRX is $11.30 and 52 week low is $4.37.
When is next earnings date of CVRx Inc(CVRX)?
The next earnings date of CVRx Inc(CVRX) is 2026-08-04 Est..
Does CVRx Inc(CVRX) pay dividends? If so, how much?
CVRx Inc(CVRX) does not pay dividend.
Guru Commentaries on NAS:CVRX
No articles.
Press Release
Articles on CVRx Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers